ABOUT US

Gesynta Pharma develops pharmaceutical treatments targeting chronic inflammation in a wide range of diseases

Gesynta Pharma is a Swedish pharmaceutical company dedicated to developing innovative drug candidates that reduce inflammation and pain, offering safe and effective treatments for serious diseases, with a particular focus on endometriosis. The company's experienced team of drug developers combines excellence in research and development with a strong entrepreneurial spirit to build a clinical pipeline based on a robust scientific platform. Based on research originating from Karolinska Institutet in Stockholm, the company has advanced a portfolio of drug candidates with a unique and validated mechanism of action to clinical stage and is well-positioned to deliver both patient and shareholder value.
Read more about our development projects. 

Experienced leadership

The members of Gesynta Pharma's management team and board of directors have extensive experience from senior positions in leading pharmaceutical companies and deep knowledge of drug development, all the way from preclinical research phase to commercialization of approved drugs.

Executive Team Board

Strong investor base

The company’s major shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, and other internationally renowned specialist investors.

Our lead candidate: vipoglanstat

Vipoglanstat (GS-248) is being developed as a non-hormonal, non-opioid, disease-modifying treatment of endometriosis. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and potent inhibition of the inflammation-related enzyme mPGES-1. Based on these results and robust data from a preclinical proof-of-concept study in an advanced disease model of endometriosis, we are preparing a phase II clinical trial with vipoglanstat in endometriosis patients.

Read more

Second-generation drug candidates

Gesynta Pharma’s pipeline presents a broad range of opportunities based on unique anti-inflammatory and pain-relieving properties. The first compound in this new generation of drug candidates, GS-073, is ready to enter clinical phase I for a yet to be specified chronic inflammatory disease.

Read more

Learn more about Gesynta Pharma

Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our management

The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.

Endometriosis

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our portfolio

Our lead drug candidate vipoglanstat is in clinical phase II for endometriosis, while GS-073 is ready to enter clinical phase I for chronic inflammatory pain.